Share-based Payment Arrangement, Expense in USD of Humacyte, Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Humacyte, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q3 2020 to Q3 2025.
  • Humacyte, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $2.51M, a 61.7% increase year-over-year.
  • Humacyte, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $9.13M, a 56% increase year-over-year.
  • Humacyte, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6.14M, a 10.1% decline from 2023.
  • Humacyte, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6.83M, a 10.4% increase from 2022.
  • Humacyte, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.18M, a 39.1% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Humacyte, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $9.13M $2.51M +$958K +61.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 $8.17M $2.43M +$997K +69.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $7.17M $2.49M +$1.03M +71% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $6.14M $1.69M +$288K +20.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 $5.85M $1.55M -$220K -12.4% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 $6.07M $1.44M -$404K -21.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $6.47M $1.45M -$355K -19.6% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $6.83M $1.41M -$264K -15.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 $7.09M $1.77M +$296K +20.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $6.8M $1.84M +$350K +23.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $6.45M $1.81M +$262K +16.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $6.18M $1.67M -$1.14M -40.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $7.33M $1.48M -$401K -21.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $7.73M $1.49M -$1.44M -49.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $9.17M $1.55M -$981K -38.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $10.1M $2.81M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 $1.88M +$707K +60.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $2.93M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $2.53M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q3 2020 $1.17M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15

Humacyte, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $6.14M -$691K -10.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 $6.83M +$644K +10.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 $6.18M -$3.96M -39.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $10.1M +$5.45M +116% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 $4.69M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.